VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
FTRE
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
FTREFortrea Holdings Inc.
$17.28$1.6B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders

FTRE logoFortrea Holdings Inc.(FTRE)Earnings, Financials & Key Ratios

FTRE•NASDAQ
$17.58
Price updated Jul 2, 2026
SectorHealthcareIndustryBiotechnologySub-IndustryBiopharma Services and CROs
AboutFortrea Holdings Inc., a contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide. It operates through two segments: Clinical Services and Enabling Services. The Clinical Services segment provides across the clinical pharmacology and clinical development spectrum. The Enabling Services segment provides patient access and clinical trial technology solutions to customers that streamline complex randomization and optimize the trial drug supply process. The company offers delivery models that include full service, functional service provider, and hybrid service structures. It also offers phase I-IV clinical trial management, differentiated technology enabled trial solutions, and post approval services. The company serves pharmaceutical, biotechnology, and medical device organizations. Fortrea Holdings Inc. was incorporated in 2023 and is based in Durham, North Carolina.Show more
  • Revenue$2.72B+1.0%
  • EBITDA$47M+163.2%
  • Net Income-$986M-200.2%
  • EPS (Diluted)-10.81-194.6%
  • Gross Margin15.63%-21.1%
  • EBITDA Margin1.74%+162.6%
  • Operating Margin-1.12%+81.3%
  • Net Margin-36.21%-197.2%
  • ROE-102.41%-379.6%

FTRE Price & Volume

Fortrea Holdings Inc. (FTRE) stock price & volume — 10-year historical chart

Loading chart...

Persistent Operational Volatility Challenges Fortrea's Independent Path

Investment Thesis • Updated 2026Q1

VerdictNegative
Growth:Contracting
Profitability:Negative
Financial:Strained
Cash Flow:Mixed
Primary Risk:Persistent operating margin deficits

Key Thesis Takeaways

  • Fortrea Holdings faces a challenging transition as an independent entity, characterized by persistent revenue contraction and structural margin deficits that hinder profitability.
  • While the company has successfully reduced its total debt to $75.4 million as of 2026Q1, the erosion of its equity base from $1.7 billion in 2023Q4 to $525.9 million raises significant concerns regarding long-term value creation.
  • Investors should monitor whether the company can stabilize its FSP-heavy service model and reverse the trend of negative operating margins, which have plagued eight of the last ten quarters.

Verdict Logic

the company's inability to achieve consistent profitability, evidenced by a -3.7% net margin in 2026Q1 and recurring net losses, suggests that fundamental risks currently outweigh potential recovery catalysts.

FTRE Growth Metrics

Fortrea Holdings Inc. (FTRE) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years-
5 Years-
3 Years-1.35%
TTM0.86%

Profit CAGR

10 Years-
5 Years-
3 Years-
TTM43.46%

EPS CAGR

10 Years-
5 Years-
3 Years-
TTM44.21%

Return on Capital

10 Years0.55%
5 Years0.55%
3 Years-1.91%
Last Year-1.38%

FTRE Recent Earnings

Fortrea Holdings Inc. (FTRE) EPS & revenue vs analyst estimates — last 4 quarters

Full history →
●Beat EPS 5/12 qtrs (42%)●Beat Revenue 7/12 qtrs (58%)
Q2 2026Latest
May 5, 2026
Metric
Actual
Est
EPS
$0.16+433.3%
$0.03
Rev
$637M+1.3%
$629M
Q1 2026
Feb 26, 2026
Metric
Actual
Est
EPS
$0.09-43.8%
$0.16
Rev
$661M-0.7%
$665M
Q4 2025
Nov 5, 2025
Metric
Actual
Est
EPS
$0.12-25.0%
$0.16
Rev
$701M+5.4%
$665M
Q3 2025
Aug 6, 2025
Metric
Actual
Est
EPS
$0.19+216.7%
$0.06
Rev
$710M+13.9%
$623M
QuarterDateEPS (Act vs Est)Revenue (Act vs Est)
Q2 2026LatestMay 5, 2026
$0.16vs $0.03+433.3%
$637Mvs $629M+1.3%
Q1 2026Feb 26, 2026
$0.09vs $0.16-43.8%
$661Mvs $665M-0.7%
Q4 2025Nov 5, 2025
$0.12vs $0.16-25.0%
$701Mvs $665M+5.4%
Q3 2025Aug 6, 2025
$0.19vs $0.06+216.7%
$710Mvs $623M+13.9%
Based on last 12 quarters of dataView full earnings history →

Latest FTRE News

Recent stock market news and headlines for Fortrea Holdings Inc. (FTRE)

GlobeNewsWire·Jun 26, 2026
Fortrea Names Jason Knoblauch as Chief Financial Officer

Jason Knoblauch will succeed Jill McConnell as chief financial officer of Fortrea Jason Knoblauch will succeed Jill McConnell as chief financial officer of Fortrea

Peers Comparison

Key metrics vs top competitors for Fortrea Holdings Inc. (FTRE)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
FTRE logoFTREFortrea Holdings Inc.Current
$17.58$1.66B-1.631%-36.21%-102.41%—
IQV logoIQVIQVIA Holdings Inc.
$203.20$34.48B25.925.87%8.33%22.11%—
CRL logoCRLCharles River Laboratories International, Inc.
$229.09$11.03B-78.73-0.85%-4.59%-5.66%—
MEDP logoMEDPMedpace Holdings, Inc.
$543.57$15.52B35.5719.97%17.19%120.89%—
PRA logoPRAProAssurance Corporation
$25.00$1.29B25.25-2.67%6.04%4.95%—
ICLR logoICLRICON Public Limited Company
$175.05$13.4B60.36-0.37%5.35%4.7%—

Compare FTRE vs Peers

Fortrea Holdings Inc. (FTRE) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs IQV

Most directly comparable listed peer for FTRE.

Scale Benchmark

vs TMO

Larger-name benchmark to compare FTRE against a more recognizable public peer.

Peer Set

Compare Top 5

vs IQV, CRL, MEDP, PRA

FTRE SEC Filings & Documents

Fortrea Holdings Inc. (FTRE) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

May 5, 2026·SEC

Material company update

Feb 26, 2026·SEC

Material company update

Nov 20, 2025·SEC

10-K Annual Reports

3
FY 2026

Feb 26, 2026·SEC

FY 2025

Mar 3, 2025·SEC

FY 2024

Mar 13, 2024·SEC

10-Q Quarterly Reports

6
FY 2026

May 5, 2026·SEC

FY 2025

Nov 5, 2025·SEC

FY 2025

Aug 6, 2025·SEC

Get notified when FTRE posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

FTRE Frequently Asked Questions

Fortrea Holdings Inc. (FTRE) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is Fortrea Holdings Inc.'s revenue?

Fortrea Holdings Inc. (FTRE) reported $2.71B in revenue for fiscal year 2025. This represents a 11% decrease from $3.06B in 2021.

How fast is Fortrea Holdings Inc. growing?

Fortrea Holdings Inc. (FTRE) grew revenue by 1.0% over the past year. Growth has been modest.

Is FTRE profitable?

Fortrea Holdings Inc. (FTRE) reported a net loss of $446.9M for fiscal year 2025.

Dividend & Returns
What is FTRE's return on equity?

Fortrea Holdings Inc. (FTRE) has a return on equity (ROE) of -102.4%. Negative ROE indicates the company is unprofitable.

What is Fortrea Holdings Inc.'s free cash flow?

Fortrea Holdings Inc. (FTRE) generated $215.4M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

What if you invested $1,000 in FTRE back in 2021?

Total return calculator · dividends reinvested · 5+ years of data

See returns →